Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study.
- DOI
- 10.1080/13543784.2026.2628208
- Published
- 2026 Jan-Feb
- Container
- Expert opinion on investigational drugs
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/13543784.2026.2628208,
title = {Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study.},
author = {Hasunuma T and Yagi M and Nakamichi N and Blauvelt A and Thaçi D and Suh J and Cha J and Noh I and Lee E and Papp KA},
year = {2026},
journal = {Expert opinion on investigational drugs},
doi = {10.1080/13543784.2026.2628208},
url = {https://doi.org/10.1080/13543784.2026.2628208}
}RIS
TY - JOUR TI - Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study. AU - Hasunuma T AU - Yagi M AU - Nakamichi N AU - Blauvelt A AU - Thaçi D AU - Suh J AU - Cha J AU - Noh I AU - Lee E AU - Papp KA PY - 2026 JO - Expert opinion on investigational drugs DO - 10.1080/13543784.2026.2628208 UR - https://doi.org/10.1080/13543784.2026.2628208 ER -
APA
T, H., M, Y., N, N., A, B., D, T., J, S., J, C., I, N., E, L., & KA, P. (2026). Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study.. Expert opinion on investigational drugs. https://doi.org/10.1080/13543784.2026.2628208
Source records
- pubmed · retrieved 2026-09-26T19:41:40.736Z
- europe-pmc · retrieved 2026-09-26T19:41:40.735Z